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ABSTRACT
Diabetes mellitus is a chronic and metabolic disorder which results from defects in a section of insulin, action of insulin, or both. Primarily drugs are 
used to control the symptoms and save life. Secondary aims are to prevent long-term diabetic complications and by eliminating various risk factors to 
increase longevity. In type I diabetes mellitus, new innovative therapies such as pancreatic transplantation, pancreatic islet transplantation, stem cell 
therapy, transdifferentiation, and gene therapy are discussed, and regarding type II diabetes mellitus, treatment is based on drugs which stimulates 
the secretion of insulin such as conventional therapy, antihypoglycemic agents such as insulin, insulin secretagogues, and insulin sensitizers, 
α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, and a list of patents for the treatment of 
diabetes mellitus are discussed in this review article.
Keywords: Diabetes mellitus, Hypoglycemic agents, Insulin secretagogues, Insulin sensitizers, Patents, Stem cell therapy.
INTRODUCTION
Diabetes mellitus
Diabetes mellitus is a metabolic and chronic disorder which diminishes 
the activity of energy utilization from food by the human body for 
lifetime. It is a chronic metabolic disorder, which is characterized by 
chronic hyperglycemia, deficiency of insulin, and resistance to insulin. 
With diabetes mellitus, either your body loses the ability to produce 
insulin or there occurs improper use of the produced insulin. There are 
two major types of diabetes.
1. Type I diabetes mellitus (insulin-dependent diabetes mellitus 
[IDDM]).
2. Type II diabetes mellitus (non-insulin-dependent diabetes mellitus 
[NIDDM]).
Type I diabetes mellitus
It is also called insulin-dependent diabetes or juvenile diabetes. It causes 
autoimmune and kidney disease, heart stroke, and nerve damage to the 
nerves which are present in feet. In this type, diabetes body’s immune 
system attacks its own pancreas and stops the insulin secretion. One of 
the reasons for this type of diabetes is a genetic predisposition. It can 
be also the result of faulty pancreatic β-cells. Medical risks associated 
with this type diabetes are damage to the small blood vessels which are 
present in the eyes, kidneys, and nerves.
Type II diabetes mellitus
It is also called as NIDDM and adult-onset diabetes. It is the most 
common and milder form of diabetes than type I diabetes mellitus. 
Nevertheless, it still can cause major health problems, especially the 
small blood vessels which are present in the eyes, nerves, and kidneys. 
It also increases the risk of heart diseases and heart dose. With this 
type II diabetes, the body’s pancreas normally produces the insulin 
either the produced insulin is not enough or the body’s cells are 
resistant to insulin [1-5].
Pancreatic transplantation
It is a surgical operation, and the normal pancreas is collected from 
an expired person and inserted into a person’s body whose pancreas 
not works properly. Pancreatic transplantations are done to treat or 
control type I diabetes mellitus. The pancreas lies in the lower part 
of the stomach. The pancreas major function is to secrete a hormone 
called insulin, which regulates or controls the sugar absorption into 
body cells. Type I diabetes mellitus results when the pancreas does 
not produce sufficient insulin, causing sugar levels in the blood rise to 
dangerous levels.
The surgical team checks the heart rate, blood oxygen, and pressure 
throughout the procedure with a heart monitor leads attached to the 
chest and blood pressure cuff on arm of the patient.
After the patient is unconscious:
• A small cut is made the center of the patient abdomen.
• The surgeon keeps the new pancreas along with a small portion of 
the small intestine into the patient’s lower abdomen.
• Then they will attach donor new sections of small intestine containing 
pancreas to  patients small intestine or donor pancreas to patient 
urinary bladder and pancreas is connected to blood vessels.
• Do not disturb the patient’s pancreas to aid digestion.
• If the patient is also receiving a kidney transplant, the blood vessels 
of the new kidney will be attached to the lower part of a patient’s 
abdomen blood vessel.
• The new ureters by which urine passes from kidneys to bladder. Unless 
patient’s own kidneys are causing major problems, such as infection 
or high blood pressure, they are not disturbed from their place.
Pancreas transplantation generally takes about 3 h. Along with that 
kidney-pancreas transplantation takes a few more hours.
Complications of the procedure
Bleeding, blood clots, infection, urinary complications, hyperglycemia, 
donated organs failure, and donated organs rejection are the 
cpmplications of the procedure.
RESULTS
After pancreas transplantation, the new pancreas produces the insulin, 
so the patient does not require insulin therapy to treat type I diabetes. 
Even though there is compatibility between patient and the donor, 
patient’s immune system will try to reject the new pancreas. To avoid 
rejection of newly transplanted pancreas, patient needs medications to 
suppress the body’s immune system the rest of life. Patients need to 
take anti-rejection drugs or immunosuppressants for the rest of life.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.28285
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Immunosuppressant’s or antirejection drugs
These are medicines or drugs that lower the body’s ability to reject 
transplanted organs. These drugs are also called as anti-rejection 
drugs.
Immunosuppressants are categorized into:
1. Induction drugs: These are powerful anti-rejection drugs used at the 
time of transplant.
2. Maintenance Drugs: These drugs are used for long term.
There are usually four classes of maintenance drugs:
Antiproliferative agents
Azathioprine, mycophenolate mofetil, and mycophenolate sodium.
Calcineurin inhibitors
Cyclosporine and tacrolimus.




Transplanted pancreas and kidney survival rates are as follows:
Pancreas transplantation
In about 81% of people who undergoes pancreas transplantation, after 
1 year, the transplanted pancreas is still working, and after 5 years, that 
rate of working is up to 53%.
Simultaneous pancreas and kidney transplantation
In about 90% of people who receive simultaneous pancreas-kidney 
transplantation, after 1 year, the transplanted kidney and pancreas are 
still working, and after 5 years, the rate of working is up to 78%.
Pancreas transplantation after kidney transplantation
In about 87% of people who receive pancreas transplantation after 
kidney transplantation, after 1 year, the transplanted pancreas is still 
working, and after 5 years, the rate of working is up to 70%.
Diet
No dietary restrictions are required after pancreatic transplantation.
Pancreatic islets
It is also called as islets of Langerhans; these are the minute clusters of 
cells which are dispersed throughout the pancreas.
It consists of numerous types of cells including β-cells, pancreatic 
β-cells which produces the insulin hormone, and enzymes which help 
the body to digest food.
When the blood glucose or blood sugar levels increase after a meal, the 
pancreas will release insulin into the bloodstream. Insulin is required 
for absorption of glucose from the bloodstream and for conversion of 
glucose into energy.
In type I diabetes, pancreatic β-cells does not produce insulin because 
the body’s immune system attacks its own pancreas and stops secreting 
the insulin. Due to this situation, blood glucose levels will increase 
instead of being absorbed by the body cells. People who have type I 
diabetes should take insulin daily to live and to maintain the blood 
sugar levels normal.
Pancreatic islet transplantation





It is a procedure in which islets from a deceased donor pancreas 
are purified and transferred into a patient. In pancreatic islet 
allotransplantation to remove islets from a diseased donor, they 
use specialized enzymes. Then, the collected islets are purified and 
counted in the laboratory. A patient receives two transplantations with 
an average of 500,000–600,000 islets per each transplantation. After 
implantation, the β-cells in the islets start to release insulin. This type 
of transplantation is performed in patients whose type I diabetes levels 
are high and difficult to control. The main aim of this transplantation is 
to help the patients achieve normal glucose levels without daily insulin 
injections and eliminate hypoglycemia.
Pancreatic islet transplantation carried out only at hospitals which 
have USFDA authorization for clinical research on pancreatic islet 
transplantation. The radiologist performs these transplants frequently. 
The radiologist uses ultrasound and X-rays to guide the catheter 
through a small incision in the upper abdomen. Then, pancreatic islets 
are then infused through the catheter slowly into the liver. Usually, 
a patient receives a sedative and local anesthetic. In few cases, a 
surgeon performs the pancreatic islet transplantation by using general 
anesthesia. Patients regularly need two or more transplants to get a 
sufficient amount of islets to reduce or stop their need for insulin.
Pancreatic islet autotransplantation
In patients with chronic, long-lasting, and severe pancreatitis, which can be 
accomplished only by pancreatic islet autotransplantation, the procedure 
of pancreatectomy is carried out. Pancreatic islet autotransplantation 
cannot be carried out in the patients with type I diabetes. It is carried 
out in the hospital and the surgeon will administer general anesthesia 
to the patient. First and foremost, surgeon will remove the pancreas, 
followed by pancreatic islets extraction and purification. Using catheter, 
the islets are infused into the liver of the patient. Then, the infused islets 
will secrete the insulin which maintains the blood glucose levels.
The advantages of pancreatic islet autotransplantation are an 
improvement in control of the blood glucose levels and reduce the need 
for insulin injections to control the blood glucose levels and hindrance 
of hyperglycemia. Whole pancreas transplantation is the alternative for 
this method, which is performed along with the kidney transplantation. 
Whole pancreas transplantation benefits are less dependent on insulin 
and longer duration of pancreas function. The main drawbacks with 
the whole pancreas transplantation are major surgery, which involves 
major risk of complications.
Immunosuppressive or anti-rejection medications are needed to 
avoid the rejection, and it is a common problem associated with 
transplantation.
Immunosuppressive or anti-rejection medications are tacrolimus, 
sirolimus, and daclizumab . For example, immunosuppressive drugs used 
in islet transplantation contain alemtuzumab, anti-thymocyte globulin, 
basiliximab, belatacept, etanercept, everolimus, and mycophenolate mofetil.
Anti-rejection medications have immediate side effects which may 
include gastrointestinal problems, mouth sores, and stomach upset and 
risk of developing certain tumors and cancers (Fig. 1).
Diet and nutrition
The person who undergoes pancreatic transplantation should 
follow a particular diet suggested by the dietician or a health-care 
provider [6-20].
Stem cells
It is an alternative for transplantable β-cells. These stem cells have a 
remarkable capacity to develop into different cell types in the body. It 
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Fig. 1: Pancreatic islet transplantation
Fig. 2: Stem cell transplantation
Fig. 3: Embryonic stem cells
Fig. 4: Induced pluripotential stem cells
acts as an internal repair system in many tissues. When the division of 
stem cells occurs, each divided new cell has the capacity to remain as a 
stem cell or become different types of cell with a more specific function 
such as brain cells, muscle cells, and red blood cells (Fig. 2).
Stem cells are available in two potential sources:
1. Embryonic stem cells (ES).
2. Induced pluripotential stem cells.
ES cells
ES cells, induced pluripotent stem cells, and pancreas-derived stem 
cells are able to distinguish into beta-cells. Hepatic stem cell expressing 
pancreatic and duodenal homeobox-1 (PDX-1) distinguished into β-cells 
and improves excessive glucose levels in the blood of diabetic mice. ES 
cells are separated from blastocysts, and it can be distinguished into 
ectoderm, endoderm, and mesoderm cells. They can also distinguish 
into insulin-producing cells, and these cells are able to secrete insulin 
in response to glucose stimuli and to regularize the glucose levels in the 
blood of diabetic mice when it transferred into diabetic mice (Fig. 3).
The stem cell production from a pluripotent resource is called as induced 
pluripotency. For the production of pluripotent stem cells, somatic 
stem cells are reprogrammed under specific conditions; such type of 
cells is called as induced pluripotent stem cells. These cells exhibit rises 
in the activity which is similar to ES cells. These are preferred as the 
best choice for the cell-based treatment for diabetes mellitus. For the 
production of Induced pluripotent stem cells (IPSC), fibroblast cells are 
induced and later these cells are converted into pancreatic β-cells. The 
transferring of fibroblast-derived β-cells into diabetic mouse controlled 
the blood glucose levels [21-26] (Fig. 4).
Transdifferentiation
Patients fibroblasts transdifferentiation into pancreatic like cells might 
render most straight forward clinical application of reprogrammed cells 
based therapy without the concerns of HESC (human embryonic stem 
cells) or with HIPSC (human induced pluripotent stem cells). For cell 
replacement therapy, transdifferentiation has become the tendency 
to produce β-cell resources. This method depends on cellular 
reprogramming and regeneration of β-cells. Regeneration of β-cells 
will occur from different pancreatic progenitor cells in the grown 
person pancreas. Acinar ductal transdifferentiation is a mechanism 
by which acinar cells are distinguished into duct cells. In addition to 
this, acinar cells have the capability to distinguish into adipocytes 
and hepatocyte-like cells, controlled by the microenvironment. 
α-cells have the ability to convert into β-cells in zebrafish by utilizing 
β-cell ablation model. Glucagon and glucagon-like peptide-1 (GLP-1) 
have a strong effect on α-to-β cell transdifferentiation, and β-to-α 
cell transdifferentiation is also feasible in the case of opposition. 
Suppression of pancreatic duodenal homeo box 1, forkhead box 01, 
NK2 homeobox 2 and transdifferentiated into α-cells and induced 
the dedifferentiation of β-cells. δ-cells of the pancreas are capable of 
transdifferentiate into insulin-producing cells [27-35] (Fig. 5).
Gene therapy
A foreign gene is introduced into any cell type in the body, permitting 
it to produce insulin which is called as gene therapy. The introduced 
gene would be either insulin gene itself or a gene encoding factor which 
activates the insulin gene, thereby allowing the ectopic production of 
insulin. Differentiation of stem cell into β-cells in the patient by means 
of molecular intervention would be included in this gene therapy.
Cell replacement therapy
One of the most potent therapies for diabetes mellitus is cell replacement 
therapy of insulin-producing cells. This therapy includes the islet cell 
transplantation contributed by the pancreas of the donor; these cells 
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will function for years in diabetic patients. Cell replacement therapy 
encompasses all techniques that involve the expansion or creation of in 
vitro insulin-producing cells followed by their implantation in the patient. 
The cells can be from beta origin, may be immortalized to permit absolute 
expansion in culture, or manipulate the non-beta-cells to produce insulin. 
On the other hand, they can be originated from stem cells [29,35-40].









•	 α-glucosidase inhibitors (AGI)
•	 Dipeptidyl peptidase-4 (DPP-4) inhibitors
•	 Sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Insulin
People who have IDDM cannot formulate insulin because of the 
damaged or ruined β-cells in their pancreas. For that reason, patients 
who have type I diabetes will need insulin injections to allow their body 
to process glucose and to avoid complications from hyperglycemia.
Insulin types
There are different types of insulins. It categorized from rapid acting 
to long-acting insulins, from analog insulin through to human insulins. 
Insulin can be categorized based on how the insulin is derived and how 
quickly it works.
Forms of insulin
There are three forms of insulin which are available.
1. Analog insulin: Analog insulin is a laboratory-grown human insulin.
2. Animal insulin: Animal insulin comes from animals.
3. Human insulin: Human insulin is laboratory-made insulin.





This is a regular method for insulin delivery. In this method, insulin 
syringe is an injection device. The disposable, plastic syringes currently 
are available in three sizes as 30, 50, and 100 units of insulin. The 
needles are fine with the length ranging from ½ inch or more for adults 
and 3/16th of an inch for infants. This syringe is injected into the layer 
of fat just below the skin.
Insulin pen




The reusable pen is loaded with a cartridge of insulin before its use. 
150–300 units of insulin can be held in one cartridge. A cartridge 
may provide sufficient insulin based on the size of your dose which 
may last for many days. A new cartridge can be loaded after the 
usage of the previous one reusable pen can be used generally for 
many years.
Disposable pens
Disposable pens are filled with insulin and discarded after its use. 300 
units of insulin can be held in most of the disposable insulin pens which 
are more convenient than the reusable pens because no need of filling 
any cartridges. These are most costlier compared to reusable pens.
Infusion
In a hospital under the medical supervision, insulin may be injected 
directly into the vein. It is added to intravenous fluids, blood sugar, and 
insulin doses which are strictly monitored by the specialists. It is only 
given during the surgery or stay in the intensive care unit.
Insulin pump
It is also known as continuous subcutaneous insulin infusion device. 
These are the most sophisticated form of insulin delivery. Insulin pumps 
are computerized devices, small in size that is programmed to transport 
insulin under the skin. These are durable and last for many years, but 
certain components of the insulin pump and the insulin supply are 
changed every few days.
Fig. 7: Mechanism of the action of sulfonylureas
Fig. 5: Transdifferentiation of pancreatic exocrine cells
Fig. 6: Routes of insulin administration
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Insulin secretagogues
These are one type of medicine used for type II diabetes treatment. 
A person with type II diabetes does not make sufficient insulin or body 
cells have insulin resistance. In that condition, insulin secretagogues 
help the pancreas to secrete or release insulin. Insulin helps to maintain 
blood glucose levels normal.
Sulfonylureas
These are the first oral medicine available for the treatment of type 
II diabetes mellitus. For diabetes treatment, carbutamide is the first 
clinically useful sulfonylurea [36,41-43].
Types of sulfonylureas
• First-generation sulfonylureas.
• Second-generation sulfonylureas. Drugs comes under sulfonylureas 
are given in table 1
• Third-generation sulfonylureas.
Mechanism of action
By stimulating the pancreas to more insulin release, these are effective 
only when the β-cell activity is still present. It blocks the adenosine 
triphosphate (ATP)-sensitive K+ channels in β-cells and decreases 
the K permeability of β-cells. This action causes the Ca+2 entry into 
the cell and depolarization of the cells, which causes improvement in 
the secretion of the insulin. The released insulin will reduce the blood 
glucose levels [41,42,44-47] (Fig. 7).
Fig. 9: Mechanism of action of thiazolidinedione
Fig. 8: Mechanism of the action of metformin












Table 2: Drugs used in meglitinide category
Generic name Brand name
Repaglinide Prandin
Nateglinide Starlix
Table 3: Drugs used in thiazolidinedione category
Generic name Brand name
Rosiglitazone Avandia
Pioglitazone Actos
Table 4: Drugs used in AGI category




Table 5: Drugs used in DPP‑4 inhibitor category






Table 6: Drugs used in SGLT2 inhibitors






These are oral medicines utilized for the treatment of type II diabetes 
mellitus. Meglitinides work similarly as sulfonylureas. It reduces 
the blood glucose levels by increasing the secretion of insulin by the 
pancreas. These are fast acting and disperse quickly, so they frequently 
must be taken many times a day.
Currently, two forms of meglitinides are available in the market 
(Table 2).
Mechanism of action
It stimulates the pancreatic insulin secretion and, after meals, reduces 
the glucose levels rise in the blood [48-53].
Insulin sensitizers
Biguanides
This is one of the classes of medications used for the treatment of 
type II diabetes mellitus. It starts to lower the blood glucose by two 
ways. Primarily, it starts to decrease the amount of glucose produced by 
the liver. It increases the glucose absorption by muscle cell and reduces 
the insulin resistance.
The only drug used in biguanides is metformin
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Fig. 10: Mechanism of the action of dipeptidyl peptidase‑4 inhibitors
Table 7: List of patents in the treatment of diabetes
Title Patent No. Inventors Year References
Substituted aromatic compounds 
and pharmaceutical compositions 
for the prevention and treatment 
of diabetes
WO2016054726 A1 Gagnon et al. April 14, 2016 Substituted aromatic compounds and 
pharmaceutical compositions for the 
prevention and treatment of diabetes, 
WO2016054726 A1, April 14, 2016
DPP-4 inhibitor combined with a 
further antidiabetic agent, tablets 
compromising such formulations, 
their use, and process for their 
preparation
US9155705 B2 Friedl et al. October13, 2015 Friedl et al. DPP-4 inhibitor combined 
with a further antidiabetic agent, tablets 
compromising such formulations, their 
use, and process for their preparation, 
US9155705 B2, 2015
Diabetes therapy US9149478 B2 Klein et al. October 06, 2015 Klein et al. Diabetes Therapy,




US9034883 B2 Klein et al. May, 19 2015 Vasoprotective and cardioprotective 
antidiabetic therapy, US9034883 B2, 19, 
May 2015.
Combination therapy for the 
treatment of diabetes and related 
conditions
US8513264 B2 Mark et al. August 20, 2013 Combination therapy for the treatment of 
diabetes and related conditions, US8513264 
B2, August 20, 2013
Heterocyclic receptoragonist for 
the treatment of diabetes and 
related conditions
US8288384 B2 Chen et al. October 16, 2012 Heterocyclic receptoragonist for the 
treatment of diabetes and related conditions, 
US8288384 B2, October 16, 2012
Uses of DPP-4 inhibitors US8232281 B2 Klaus et al. July 31, 2012 Uses of DPP-4 inhibitors, US8232281 B2, 
July 31, 2012
N-linked heterocyclic receptor 
agonists for the treatment of 
diabetes and metabolic disorders
US8183381 B2 Ma and Rabbat May 22, 2012 N-linked heterocyclic receptor agonists for 
the treatment of diabetes and metabolic 
disorders, US8183381 B2, May 22, 2012
System and method for 
distinguishing among cardiac 
ischemia, hypoglycemia, 
and hyperglycemia using an 
implantable medical device
US8180441 B2 Gill et al. May 15, 2012 System and method for distinguishing 
among cardiac ischemia, hypoglycemia, and 
hyperglycemia using an implantable medical 
device, US8180441 B2, May 15, 2012
Neural stimulation for treatment 
of metabolic syndrome and type II 
diabetes
US7689277 B2 Dobak III March 30, 2010 Neural stimulation for the treatment of 
metabolic syndrome and type II diabetes, 
US7689277 B2, March 30, 2010
Combination therapy for the 
treatment of diabetes and related 
conditions
WO2010029089 A2 Mark et al. March 18, 2010 Combination therapy for the treatment 
of diabetes and related conditions, 
WO2010029089 A2, March 18, 2010
DPP-4: Dipeptidyl peptidase-4
Mechanism of action
It reduces the blood sugar levels by increasing the fat, liver, and 
muscle sensitivity to insulin. These are referred as insulin sensitizers 
or euglycemic. It will take the time to show their therapeutic action. 
The main side effects of this drugs are fluid retention, weight gain, and 
anemia [54-58] (Fig. 9).
AGI
These are widely used in type II diabetes treatment. It delays the 
carbohydrate absorption from the small intestine and reduces the 
Metformin
Mechanism of action
Metformin starts its action in two ways. Primarily, it helps to stop the 
production of new glucose from the liver. It also helps to control the 
insulin sensitivity by transporting the glucose into cells effectively 
(Fig. 8).
Thiazolidinediones
These are new form of drugs for type II diabetes treatment (Table 3).
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postprandial blood glucose levels and insulin levels.
Drugs come under AGIs which are given in Table 4.
AGIs reversibly hinder a number of α-glucosidase enzymes, 
consequently delaying the absorption of glucose from the gut. The 
therapeutic effects of AGI are not only based on a delayed complex 
carbohydrate digestion but also on the metabolic effects of colonic 
starch fermentation. Acarbose is the most widely prescribed AGI. The 
other AGIs are voglibose and miglitol [59-63].
Novel antidiabetic agents
DPP-4 inhibitors
DPP4 inhibitors are a class of oral hypoglycemic agents which block 
DPP4 enzyme secreted by brush border of the intestine. These are used 
for type II diabetes treatment (Table 4).
Mechanism of action
GLP-1 and incretin secreted by the small intestine. DPP4 enzyme 
stops the GLP-1and incretin release. DPP4 inhibitors inhibit the DPP4 
enzyme production, and because of this action, GLP-1 and incretin 
production increase in the body. GLP-1 increases the insulin production 
by inhibiting the glucagon release and reduces the blood sugar 
levels [64-69] (Fig. 10).
SGLT2 inhibitors
Mechanism of action
SGLT2 inhibitors are the latest class of oral hypoglycemic agents for 
type II diabetes mellitus treatment (Table 6).
SGLT2 inhibitor blocks the SGLT2 protein involved in the reabsorption 
of glucose up to 90% in the proximal renal tubule. It results in 
increased excretion of the glucose from renal tube and lowers glucose 
level in the blood. These also increase the insulin sensitivity, decrease 
gluconeogenesis, and improve insulin release from pancreatic 
β-cells [70-75] currently available patents are presented in (Table 7).
CONCLUSION
Diabetes mellitus is a slow killer with no curable treatments. On 
the other hand, its complications can be cut down through proper 
understanding and appropriate treatment. Three major complications 
are related to heart attack, kidney damage, and blindness. It is 
necessary to keep that the blood sugar levels of a patient should be 
normal to avoid any complications. One of the disadvantages by keeping 
the blood glucose level will lead to hyperglycemia that creates many 
severe complications. The objective of this article is to provide an idea 
about the current status of diabetes mellitus research and innovative 
therapies for the cure.
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